trending Market Intelligence /marketintelligence/en/news-insights/trending/BtcZibOhgaQAefxKTe0qvA2 content esgSubNav
In This List

Moody's: Pfizer's sale of consumer healthcare business is positive for liquidity

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


Moody's: Pfizer's sale of consumer healthcare business is positive for liquidity

Moody's said a sale by Pfizer Inc. of its consumer healthcare business would have a positive impact on the company's liquidity.

The rating agency believes that Pfizer will have flexibility in deciding how to redeploy the proceeds from the asset sale, which would outweigh the modest loss of earnings and product diversification from the business.

Moody's said the sale of the business does not have any impact on Pfizer's ratings and outlook.